Profile cover photo
Profile photo
TCTMD - The Source for Interventional Cardiovascular News and Education
47 followers -
The Source for Interventional Cardiovascular News and Education
The Source for Interventional Cardiovascular News and Education

47 followers
About
Posts

Post has attachment
Spin to Win: Results From Late Breaking Meeting Trials Often Overstated

A new review picks apart the positive spin that characterized several top trial presentations at the recent American College of Cardiology meeting. #cardiology #interventional #cardiovascular


https://www.tctmd.com/news/spin-win-results-late-breaking-meeting-trials-often-overstated
Add a comment...

Find the latest news and slide presentations from the most recent cardiology meetings around the world.


Heart Rhythm Scientific Sessions 2018

https://www.tctmd.com/conference/hrs-2018

EAS 2018 (European Atherosclerosis Society)

https://www.tctmd.com/conference/eas-2018

SCAI 2018 Scientific Sessions

https://www.tctmd.com/SCAI2018
Add a comment...

Post has attachment
PCI Public Reporting: Where Some Point to Problems, Others Propose Solutions

Many interventionalists say reporting today falls short of its goals but argue physicians need to stay engaged in the process, lest others fill the void. #cardiology #interventional #cardiovascular


https://www.tctmd.com/news/pci-public-reporting-where-some-point-problems-others-propose-solutions
Add a comment...

Post has attachment
Biology in the Back Seat: EAS 2018 Opens With Calls for a Big-Picture Approach to CVD Prevention

Given the known economic and social issues, experts agree that prevention efforts on a global scale need to take a wider view than lipid-lowering drugs. #cardiology #cardiovascular #interventional

https://www.tctmd.com/news/biology-back-seat-eas-2018-opens-calls-big-picture-approach-cvd-prevention
Add a comment...

Post has attachment
Andexanet Alfa, First Reversal Agent for Factor Xa Inhibitors, Finally Gains FDA Approval

The agent is the second antidote approved for the NOACs, joining idarucizumab, dabigatran’s reversal agent. #cardiology #interventional #cardiovascular

https://www.tctmd.com/news/andexanet-alfa-first-reversal-agent-factor-xa-inhibitors-finally-gains-fda-approval
Add a comment...

Don't miss the latest slide presentations from CIT 2018 (China Interventional Therapeutics in Partnership with TCT)

https://www.tctmd.com/conference/cit-2018
Add a comment...

Post has attachment
ORBITA: A Randomized, Sham-Controlled Trial of PCI in Patients With Coronary Artery Disease

C. Michael Gibson gets the full story from Rasha Al-Lamee on one of the most talked about trials of 2017. #cardiology #interventional #cardiovascular


https://www.tctmd.com/audio/orbita-randomized-sham-controlled-trial-pci-patients-coronary-artery-disease
Add a comment...

Post has attachment
TCTMD’s Top 10 Most Popular Stories for April 2018


ORBITA continued to surprise and device news dominated in a month that offered an unusually diverse line-up of stories on TCTMD. #cardiology #interventional #cardiovascular


https://www.tctmd.com/news/tctmds-top-10-most-popular-stories-april-2018
Add a comment...

Post has attachment
Don't miss the TCTMD news coverage from SCAI 2018 Scientific Sessions

https://www.tctmd.com/SCAI2018
Add a comment...

Find the latest slide presentations from the Echocardiography Conference: State-of-the-Art 2018 at TCTMD.

https://www.tctmd.com/conference/echo-2018
Add a comment...
Wait while more posts are being loaded